Cingulate therapeutics ipo
WebDec 9, 2024 · That price was the low end of an already revised range of $6 to $8. Cingulate had originally planned to offer 4.5 million shares at a $10 to $12 range, then lowered the … WebApr 10, 2024 · Market Average Movement. 6.4%. 10% most volatile stocks in US Market. 16.2%. 10% least volatile stocks in US Market. 2.9%. Stable Share Price: CING is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 22% a week. Volatility Over Time: CING's weekly volatility has increased from 16% to 22% over the …
Cingulate therapeutics ipo
Did you know?
WebAbout Cingulate®. Cingulate® (CTx®)is a Phase 3 clinical stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery … WebSep 24, 2024 · Cingulate ( NASDAQ: CING) has filed to raise $57.5 million in an IPO of its common stock, according to an S-1 registration statement. The firm is developing Precision Timed Release [PTR] drug ...
WebSep 14, 2024 · Prior to the closing of this IPO, the company will affect a “reorganization merger” in which Cingulate Inc. will acquire Cingulate Therapeutics LLC (CTx) through … WebCingulate Therapeutics, LLC (CTx) is a privately held, clinical-stage biopharmaceutical company focused on the development of innovative new products utilizing the Company’s disruptive, proprietary Precision Timed Release™ (PTR™) drug delivery platform technology incorporating a proprietary Erosion Barrier Layer (EBL) enabling the creation of true once …
WebOct 26, 2024 · KANSAS CITY, Kan., Oct. 26, 2024 /PRNewswire/ -- Cingulate Therapeutics, a privately-held, clinical-stage, biopharmaceutical company focused on the development of innovative new products for... Web1y Target Est. 5.88. Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return ...
WebMorristown, New Jersey. Craig S. Gilgallon is a Co-Founder of Cingulate Therapeutics and serves as General Counsel, Chief Legal Officer and …
WebCingulate Therapeutics has raised a total of $7.6M in funding over 3 rounds. Their latest funding was raised on Jul 11, 2024 from a Venture - Series Unknown round. Cingulate … portable sideline benchWebDec 8, 2024 · Cingulate Inc. is a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to … portable sign rentals near meWebOct 4, 2024 · The IPOs of neuroscience biotech Cingulate and Cognition Therapeutics, ... Shares of Verve Therapeutics — the year's 10th biotech IPO by size — are up more … irs cnc programWebJul 13, 2024 · Cingulate's stock was trading at $1.00 at the beginning of the year. Since then, CING stock has decreased by 3.8% and is now trading at $0.9619. View the best … irs clothing donation value goodwillWebSep 30, 2024 · Cingulate (NASDAQ: CING ), the biotech company that is developing formulations of stimulant drugs for ADHD, is making its public debut soon. Here are 7 key things to know about the upcoming CING... portable silicone rig with bangerWebApr 10, 2024 · Analyst Forecast. According to 10 analysts, the average rating for CING stock is "Buy." The 12-month stock price forecast is $5.99, which is an increase of 508.12% … irs clothing donation formWebSep 30, 2024 · Summary. Cingulate has filed proposed terms for a $50 million IPO. The firm is seeking to develop improved drug delivery technologies and pair them with existing approved drugs for ADHD. portable sidewalk ramp